ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
Launched by SOUTHEAST UNIVERSITY, CHINA · Aug 31, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well antifungal drugs work for patients who have a serious infection called invasive aspergillosis, which is caused by a type of fungus. The goal is to understand the current situation and outcomes for critically ill patients dealing with this infection. The trial is currently looking for participants aged 18 and older who have been diagnosed with invasive aspergillus infection. However, pregnant individuals are not eligible to participate.
If you or someone you know is considering joining this study, you can expect to help researchers learn more about the effectiveness of antifungal treatments in a real-world setting. This information could be very important for improving care for future patients with similar infections. The trial is open to all genders, and participation could contribute to better understanding and management of this serious health condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\>18 year-old
- • Diagosed as invasive aspergillus infection
- Exclusion Criteria:
- • Pregnant
About Southeast University, China
Southeast University, located in Nanjing, China, is a prestigious institution renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university leverages its robust academic resources and state-of-the-art facilities to conduct clinical trials that aim to address pressing healthcare challenges. Southeast University actively engages in partnerships with healthcare organizations and industry leaders to facilitate cutting-edge research, enhance patient outcomes, and contribute to the global medical community. Through its dedicated focus on ethical standards and scientific rigor, Southeast University is poised to make significant contributions to the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Trial Officials
Jingyuan Xu, M.D.
Principal Investigator
Southeast University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported